What is the difference between Mounjaro and Wegovy?
Both Mounjaro and Wegovy are safe and effective weight loss medications that help to reduce appetite, curb cravings, and, when used alongside diet and lifestyle factors, help you to lose weight.
Mounjaro
- Mounjaro contains the active ingredient Tirzepatide
- It is a revolutionary weight-loss injection that offers a clinically proven approach to managing obesity.
- It was developed by the pharmaceutical company Eli Lilly.
- It is a single use, once-weekly injectable treatment designed to regulate appetite and metabolism, providing a targeted solution for sustainable weight loss.
- Mounjaro is indicated for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial BMI ≥30 kg/m2 (obesity) or ≥27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition.
- Mounjaro is a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist and glucagon-like peptide-1 (GLP-1) receptor agonist. It is a first in a new class of treatments for weight loss and works by suppressing appetite, making you feel less hungry, resulting in weight loss.
Wegovy
- Wegovy contains the active ingredient Semaglutide.
- It is a revolutionary weight-loss injection that offers a clinically proven approach to managing obesity.
- It was developed by the pharmaceutical company Novo Nordisk.
- It is a once-weekly injectable treatment designed to regulate appetite and metabolism, providing a targeted solution for sustainable weight loss.
- Until recently, healthcare professionals would prescribe semaglutide under the brand name Ozempic (which is licensed to treat type 2 diabetes) ‘off-label’ to treat obesity.
- However, Semaglutide now has an additional product license under the brand name Wegovy, which is specifically licensed for the management of overweight and obesity, so off-label use of ozempic is no longer required.
- Wegovy is indicated for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial BMI ≥30 kg/m2 (obesity) or ≥27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition.
